Profile data is unavailable for this security.
About the company
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
- Revenue in USD (TTM)7.12m
- Net income in USD-54.65m
- Incorporated1999
- Employees168.00
- LocationInnate Pharma SA117 avenue de Luminy, Bp 30191MARSEILLE 13009FranceFRA
- Phone+33 430303030
- Fax+33 430303000
- Websitehttps://www.innate-pharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rani Therapeutics Holdings Inc | 1.20m | -28.32m | 150.69m | 105.00 | -- | -- | -- | 125.57 | -0.7906 | -0.7906 | 0.0322 | -0.1093 | 0.0447 | -- | -- | 11,428.57 | -177.34 | -64.50 | -603.19 | -106.31 | -- | -- | -3,966.50 | -6,123.18 | -- | -14.32 | 8.66 | -- | -- | 0.9816 | 11.63 | -- | -29.88 | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -133.35m | 152.04m | 61.00 | -- | 1.63 | -- | -- | -2.21 | -2.21 | 0.00 | 1.54 | 0.00 | -- | -- | 0.00 | -65.18 | -33.77 | -72.61 | -35.61 | -- | -- | -- | -21,273.47 | -- | -- | 0.2475 | -- | -- | -- | -95.39 | -- | -- | -- |
| Century Therapeutics Inc | 113.34m | -26.48m | 152.96m | 140.00 | -- | 0.8587 | -- | 1.35 | -0.3086 | -0.3086 | 1.32 | 2.04 | 0.3579 | -- | -- | 809,550.00 | -8.36 | -33.69 | -8.95 | -36.94 | -- | -- | -23.36 | -3,876.28 | -- | -- | 0.00 | -- | 194.81 | -- | 7.40 | -- | -42.55 | -- |
| ProQR Therapeutics NV | 19.08m | -50.52m | 153.80m | 166.00 | -- | 2.32 | -- | 8.06 | -0.4858 | -0.4858 | 0.1837 | 0.6288 | 0.139 | -- | 9.70 | 114,910.10 | -36.82 | -29.87 | -53.74 | -35.27 | -- | -- | -264.83 | -501.81 | -- | -- | 0.2242 | -- | 105.20 | 58.84 | 1.27 | -- | 19.58 | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -10.27m | 160.06m | 31.00 | -- | 3.42 | -- | -- | -0.0993 | -0.0993 | 0.00 | 1.52 | 0.00 | -- | -- | 0.00 | -65.28 | -46.29 | -73.32 | -48.06 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 68.95 | -- | -- | -- |
| Kalaris Therapeutics Inc | 0.00 | -51.71m | 161.78m | 6.00 | -- | 3.86 | -- | -- | -87.38 | -87.38 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -50.77 | -52.59 | -52.70 | -57.65 | -- | -- | -- | -- | -- | -- | 0.4338 | -- | -- | -- | 69.14 | -- | -- | -- |
| Innate Pharma SA (ADR) | 7.12m | -54.65m | 163.34m | 168.00 | -- | 26.27 | -- | 22.94 | -0.6523 | -0.6523 | 0.0847 | 0.0662 | 0.0491 | -- | 2.25 | -- | -37.68 | -13.29 | -52.10 | -17.34 | 49.52 | 91.15 | -767.52 | -88.46 | -- | -- | 0.93 | -- | -75.68 | -28.80 | -553.51 | -- | -64.08 | -- |
| Sagimet Biosciences Inc | 0.00 | -57.67m | 164.56m | 14.00 | -- | 1.38 | -- | -- | -1.79 | -1.79 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -38.04 | -40.69 | -39.78 | -43.01 | -- | -- | -- | -6,987.70 | -- | -- | 0.00 | -- | -100.00 | -- | -63.46 | -- | -- | -- |
| MDxHealth SA | 103.07m | -31.43m | 168.29m | 312.00 | -- | -- | -- | 1.63 | -0.7275 | -0.7275 | 2.21 | -0.1669 | 0.6614 | 7.00 | 6.20 | 330,349.30 | -20.17 | -40.27 | -29.24 | -50.75 | 64.48 | 57.38 | -30.50 | -76.84 | 1.02 | -0.8112 | 1.10 | -- | 28.29 | 50.19 | 11.67 | -- | 96.87 | -- |
| Tharimmune Inc | 0.00 | -10.32m | 169.03m | 2.00 | -- | 5.25 | -- | -- | -4.11 | -4.11 | 0.00 | 0.854 | 0.00 | -- | -- | 0.00 | -159.36 | -169.40 | -225.01 | -410.04 | -- | -- | -- | -- | -- | -- | 0.0255 | -- | -- | -- | -30.89 | -- | -- | -- |
| Cartesian Therapeutics Inc | 1.93m | -50.61m | 169.54m | 66.00 | -- | -- | -- | 87.98 | -1.97 | -1.97 | 0.0743 | -1.38 | 0.0047 | -- | 0.6943 | 29,196.97 | -11.59 | -33.50 | -12.10 | -45.25 | -- | -- | -2,489.83 | -128.46 | -- | -- | -- | -- | 49.64 | 42.27 | 69.90 | -- | 186.63 | -- |
| Editas Medicine Inc | 46.38m | -199.84m | 171.81m | 246.00 | -- | 12.20 | -- | 3.70 | -2.38 | -2.38 | 0.5454 | 0.1443 | 0.1753 | -- | 11.24 | 188,548.80 | -75.51 | -34.19 | -101.13 | -38.43 | -- | -- | -430.84 | -373.02 | -- | -- | 0.8145 | -- | -58.64 | 9.50 | -54.74 | -- | 7.43 | -- |
| Zentalis Pharmaceuticals Inc | 26.87m | -149.32m | 172.68m | 166.00 | -- | 0.6828 | -- | 6.43 | -2.08 | -2.08 | 0.3743 | 3.50 | 0.0691 | -- | -- | 161,837.30 | -38.39 | -43.59 | -43.54 | -49.56 | -- | -- | -555.80 | -1,402.74 | -- | -- | 0.00 | -- | -- | -- | 43.24 | -- | -8.89 | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -12.84m | 174.99m | 8.00 | -- | 17.95 | -- | -- | -0.1136 | -0.1136 | 0.00 | 0.0774 | 0.00 | -- | -- | 0.00 | -93.18 | -57.21 | -231.54 | -73.22 | -- | -- | -- | -- | -- | -- | 0.0115 | -- | -- | -- | 32.94 | -- | 37.77 | -- |
Data as of Feb 13 2026. Currency figures normalised to Innate Pharma SA's reporting currency: US Dollar USD
0.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Jane Street Capital LLCas of 31 Dec 2025 | 92.75k | 0.10% |
| Morgan Stanley & Co. International Plcas of 31 Dec 2025 | 43.52k | 0.05% |
| Citadel Securities LLCas of 30 Sep 2025 | 20.04k | 0.02% |
| RhumbLine Advisers LPas of 31 Dec 2025 | 5.20k | 0.01% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2025 | 2.87k | 0.00% |
| GAMMA Investing LLCas of 31 Dec 2025 | 1.07k | 0.00% |
| UBS Securities LLCas of 31 Dec 2025 | 947.00 | 0.00% |
| Optiver US LLCas of 30 Sep 2025 | 101.00 | 0.00% |
| Farther Finance Advisors LLCas of 31 Dec 2025 | 10.00 | 0.00% |
| Barclays Bank Plc (Private Banking)as of 31 Dec 2025 | 1.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
